SEOM clinical guidelines for the treatment of advanced prostate cancer (2020)
Por:
del Alba A, Mendez-Vidal M, Vazquez S, Castro E, Climent M, Gallardo E, Gonzalez-Billalabeitia E, Lorente D, Maroto J, Arranz J
Publicada:
1 may 2021
Ahead of Print:
1 feb 2021
Resumen:
The treatment of advanced prostate cancer has evolved due to recent advances in molecular research and new drug development. Dynamic aberrations in the androgen receptor, DNA repair genes, PTEN-PI3K, and other pathways drive the behavior of advanced prostate cancer allowing a better selection of therapies in each patient. Tumor testing for BRCA1 and BRCA2 is recommended for patients with metastatic prostate cancer, also considering a broad panel to guide decisions and genetic counseling. In symptomatic metastatic patients, castration should be stared to palliate symptoms and prolong survival. In high-risk or high-volume metastatic hormone-naive patients, castration should be combined with docetaxel, abiraterone, enzalutamide or apalutamide. Radiotherapy to the primary tumor combined with systemic therapy is recommended in low-volume mHNPC patients. In patients with non-metastatic castration-resistant tumors, risk stratification can define the frequency of imaging. Adding enzalutamide, darolutamide or apalutamide to these patients prolongs metastasis-free and overall survival, but potential adverse events need to be taken into consideration. The choice of docetaxel, abiraterone or enzalutamide for treating metastatic castration-resistant patients depends on previous therapies, with cabazitaxel being also recommended after docetaxel. Olaparib is recommended in BRCA1/BRCA2 mutated castration-resistant patients after progression on at least one new hormonal therapy. Aggressive variants of prostate cancer respond to platinum-based chemotherapy. To optimize treatment efficiency, oncologists should incorporate all of these advances into an overall therapeutic strategy.
Filiaciones:
del Alba A:
Hosp Univ Puerta Hierro Majadahonda, Med Oncol Dept, Joaquin Rodrigo 2, Madrid 28222, Spain
Mendez-Vidal M:
Hosp Univ Reina Sofia, Maimonides Inst Biomed Res Cordoba IMIBIC, Med Oncol Dept, Cordoba, Spain
Vazquez S:
Hosp Univ Lucus Augusti, Med Oncol Dept, Lugo, Spain
Castro E:
Hosp Univ Virgen Victoria & Reg Malaga, Med Oncol Dept, Malaga, Spain
Climent M:
Fdn Inst Valenciano Oncol, Med Oncol Dept, Valencia, Spain
Gallardo E:
Univ Autonoma Barcelona, Med Oncol Dept, Parc Tauli Hosp Univ, Inst Invest & Innovacio Parc Tauli I3PT, Sabadell, Spain
Gonzalez-Billalabeitia E:
Hosp Univ Doce Octubre, Inst Imas12, Med Oncol Dept, Madrid, Spain
Univ Catolica San Antonio Murcia UCAM, Murcia, Spain
Lorente D:
Hosp Prov Castellon, Med Oncol Dept, Castellon De La Plana, Spain
Maroto J:
Hosp Univ Santa Creu & San Pau, Med Oncol Dept, Barcelona, Spain
Arranz J:
Hosp Gen Univ Gregorio Maranon, Med Oncol Dept, Madrid, Spain
hybrid, Green Published
|